The monopolistic market shaken by approval of a domestic tetravalent flu vaccine
Green Cross, a domestic vaccine manufacturer, will enter the tetravalent influenza vaccine market, which was expected to be led by GSK during this season(2015-2016).
Green Cross has started to conduct a Phase 3 clinical study last year and applied for approval from the Ministry of Food and Drug ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
